- Home
- NCLH vs ROIV Comparison
NCLH vs ROIV Comparison
Compare NCLH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCLH
- ROIV
- Stock Information
- Founded
- NCLH 1966
- ROIV 2014
- Country
- NCLH United States
- ROIV United Kingdom
- Employees
- NCLH N/A
- ROIV N/A
- Industry
- NCLH Marine Transportation
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- NCLH Consumer Discretionary
- ROIV Health Care
- Exchange
- NCLH Nasdaq
- ROIV Nasdaq
- Market Cap
- NCLH 7.1B
- ROIV 8.4B
- IPO Year
- NCLH 2013
- ROIV N/A
- Fundamental
- Price
- NCLH $19.25
- ROIV $10.82
- Analyst Decision
- NCLH Buy
- ROIV Buy
- Analyst Count
- NCLH 18
- ROIV 4
- Target Price
- NCLH $26.65
- ROIV $17.50
- AVG Volume (30 Days)
- NCLH 15.7M
- ROIV 5.8M
- Earning Date
- NCLH 04-30-2025
- ROIV 05-29-2025
- Dividend Yield
- NCLH N/A
- ROIV N/A
- EPS Growth
- NCLH 120.77
- ROIV N/A
- EPS
- NCLH 1.77
- ROIV N/A
- Revenue
- NCLH $9,415,989,000.00
- ROIV $122,585,000.00
- Revenue This Year
- NCLH $9.38
- ROIV N/A
- Revenue Next Year
- NCLH $10.38
- ROIV N/A
- P/E Ratio
- NCLH $10.77
- ROIV N/A
- Revenue Growth
- NCLH 5.57
- ROIV 140.04
- 52 Week Low
- NCLH $14.21
- ROIV $8.73
- 52 Week High
- NCLH $29.29
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- NCLH 60.41
- ROIV 50.52
- Support Level
- NCLH $18.86
- ROIV $10.58
- Resistance Level
- NCLH $19.68
- ROIV $11.77
- Average True Range (ATR)
- NCLH 0.58
- ROIV 0.33
- MACD
- NCLH 0.36
- ROIV -0.07
- Stochastic Oscillator
- NCLH 90.05
- ROIV 19.75
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.